389650.KQ Next Biomedical Co.,Ltd.
- Market cap
- KRW 225B
- P/E
- 1,009.0x
- P/B
- 4.57x
- ROE
- -3.2%
- Dividend yield
- -
- Fundamental score
- 1.6/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 389650.KQ undervalued?
Graham numberThe Graham number of Next Biomedical Co.,Ltd. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Next Biomedical Co.,Ltd. fundamental analysis
6 of 21 checks passedROE 0/2
Low return on equity (-3.2%), below 10%.
ROA 1/1
Return on assets (-2.5%) is above the industry median (-10.1%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-110.8%) is below the industry median (4.8%).
Revenue Growth 2/2
Revenue grew 80.6% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (1.3%), 40% or less.
Debt Trend 0/1
Debt to equity history is shorter than 5 years.
Cash Runway 2/2
Cash covers 10.8 years of the current cash burn.
PE vs Market 0/1
PE (1,009.0x) is above the market median (11.3x).
PE vs Industry 0/1
PE (1,009.0x) is above the industry median (28.9x).
PBV 0/1
Price to book (4.6x) is above the industry median (2.4x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 4,612.4, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Next Biomedical Co.,Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Next Biomedical Co.,Ltd.
Next Biomedical Co.,Ltd. engages in the research and development, production, and development of therapeutics, drug delivery system and drug-medical device products in South Korea. It offers hemostatic material for endoscope; and microspheres for vascular embolization. The company was founded in 2014 and is based in Incheon, South Korea.
Full company profileNext Biomedical Co.,Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Next Biomedical Co.,Ltd. annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 2.27B | 2.80B | 4.88B | 9.54B | 16.5B | 18.1B |
| Gross Profit | -625M | 284M | 2.11B | 5.82B | 11.5B | 12.6B |
| Operating Income | -6.97B | -4.86B | -7.65B | 1.52B | -720M | -4.45B |
| EBITDA | - | -4.91B | -6.48B | 3.87B | 575M | -773M |
| Net Income | -16.6B | -5.73B | -7.52B | 2.86B | -311M | -1.56B |
| EPS | -2,079 | -716 | -939 | 354 | -38 | -190 |
| Balance Sheet | ||||||
| Total Assets | 39.7B | 32.1B | 29.6B | 58.8B | 59.3B | 63.6B |
| Total Liabilities | 34.6B | 32.4B | 35.5B | 13.7B | 11.2B | 14.4B |
| Shareholders' Equity | 5.08B | -254M | -5.90B | 45.2B | 48.1B | 49.2B |
| Cash & Short-term Investments | 22.0B | 14.8B | 14.3B | 41.6B | 6.79B | 14.0B |
| Cash Flow | ||||||
| Operating Cash Flow | -5.40B | -8.21B | -4.16B | -1.20B | 1.25B | -959M |
| Capital Expenditure | 774M | 195M | 64.5M | 439M | 3.15B | 332M |
| Free Cash Flow | -6.17B | -8.40B | -4.22B | -1.64B | -1.90B | -1.29B |
| Ratios | ||||||
| ROE | -327.4% | - | - | 6.3% | -0.6% | -3.2% |
| ROA | -41.9% | -17.8% | -25.4% | 4.9% | -0.5% | -2.5% |
| Net Profit Margin | -734.1% | -205.1% | -154.1% | 30.0% | -1.9% | -8.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Next Biomedical Co.,Ltd. dividends
Next Biomedical Co.,Ltd. has not paid dividends in the last 5 fiscal years.
Who owns Next Biomedical Co.,Ltd.
- Insiders 30.08%
- Institutions 6.79%
- Public & others 63.13%
- Shares outstanding 8.28M
- Free float 5.67M
Next Biomedical Co.,Ltd. company profile
- Company name
- Next Biomedical Co.,Ltd.
- Ticker
- 389650.KQ
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 6, Venture-ro 100beon-gil, Incheon, South Korea, 22013
- Phone
- 82 3 2454 4800
- Website
- nextbiomedical.co.kr
About Next Biomedical Co.,Ltd.
Next Biomedical Co.,Ltd. engages in the research and development, production, and development of therapeutics, drug delivery system and drug-medical device products in South Korea. It offers hemostatic material for endoscope; and microspheres for vascular embolization. The company was founded in 2014 and is based in Incheon, South Korea.
Next Biomedical Co.,Ltd. management
7- Mr. Donhaeng LeeCEO & Inside Director · born 1963
- Mr. YoonGu KangChief Financial Officer · born 1977
- Ms. Eunhye LeeMD & CTO · born 1978
- Mr. Cheoljung KangChief Scientific Officer & Executive Director · born 1967
- Ziv Haskal M.D.CMO
- Joo Ha Hwang M.D., Ph.D.CMA
- Mr. Chungryeol ChoiVP & Inside Director · born 1960